RxDoctor Payments DataLook up a doctor →

Andrew Sacco, OD

Optometrist · Vestal, NYNPI 1588638597

Payments from drug & device makers

$1,781,832in general payments, 2019–2025

Across 197 payments — averaging $9044.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$1.5M
  • Bausch & Lomb Americas Inc.$176K
  • Bausch Health US, LLC$68K
  • Coopervision Inc.$51K
  • Alcon Research LLC$21K
  • Eyevance Pharmaceuticals LLC$1K
  • plus $404 from 8 others
$244,007in research payments, 2019–2025

Across 13 payments — averaging $18,770 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Coopervision Inc.$183K
  • Bausch Health US, LLC$61K

What the payments were for

  • Consulting fees$1,00068%
  • Food & beverage$47732%

General payments by program year

19
20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,781,832 in reported general payments places this provider in the 95th percentile of 2,743 optometrist providers in New York.

See all optometrist providers in New York

Medicare billing

Part B allowed, 2024
$67,331
Medicare patients
435
Services billed
5,066

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cyclosporine23$18,564
LumiganBimatoprost31$14,470
Latanoprost171$3,624
Timolol Maleate32$3,127
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$2,686
Brimonidine Tartrate24$2,583
Travoprost15$2,347
SimbrinzaBrinzolamide/Brimonidine Tart11$2,030
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat46$1,001
Bimatoprost11$873
Bacitracin11$859
Tobramycin-DexamethasoneTobramycin/Dexamethasone21$846

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$19$14,47031 claims
AlconSimbrinza$27$2,03011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,743 optometrist providers in New York.

Other optometrist in Vestal

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →